Lunit is a cutting-edge AI-powered cancer detection and treatment solution, leveraging advanced technology to improve early diagnosis and immunotherapy efficacy. Trusted globally across 3,800+ sites, Lunit's AI enhances precision oncology and boosts survival rates. Discover how Lunit is transforming cancer care with AI-driven insights.
Share:
Published:
2024-09-08
Created:
2025-04-30
Last Modified:
2025-04-30
Published:
2024-09-08
Created:
2025-04-30
Last Modified:
2025-04-30
Lunit is an AI-powered healthcare technology company focused on conquering cancer through advanced artificial intelligence solutions. Their products include AI tools for cancer detection (like Lunit INSIGHT for radiology) and AI biomarkers for immunotherapy (like Lunit SCOPE for oncology), helping improve early diagnosis and treatment efficacy.
Lunit's AI solutions are designed for healthcare professionals, including radiologists, oncologists, and researchers. Hospitals, clinics, and cancer research institutions across 50+ countries also use Lunit's technology to enhance cancer screening accuracy and optimize treatment plans for patients.
Lunit's AI is ideal for hospitals, cancer centers, and research labs needing precise cancer screening (e.g., lung or breast cancer via X-rays) or treatment optimization (e.g., immunotherapy response prediction). It’s also used in global clinical trials and telemedicine platforms to support remote diagnostics.
Lunit is a healthcare AI company focused on conquering cancer through advanced technology. Their AI solutions specialize in early cancer detection and optimizing treatment. For screening, Lunit INSIGHT products analyze radiology images to identify early-stage cancers. For treatment, Lunit SCOPE products analyze biomarkers to predict immunotherapy response. These AI tools help doctors make more accurate diagnoses and treatment decisions, ultimately improving patient outcomes.
Lunit's cancer detection AI has demonstrated high accuracy in clinical studies and is used across 3,800+ sites globally. Their technology has been validated in over 200 research studies and abstracts. Lunit's AI solutions are recognized as world-leading, having been named in CB Insights' 'Digital Health 150' for three consecutive years, which speaks to their reliability and effectiveness in cancer screening.
Lunit offers specialized AI solutions for different cancer types. Their radiology products like Lunit INSIGHT CXR detect lung abnormalities from chest X-rays, while Lunit INSIGHT MMG analyzes mammograms for breast cancer. Their oncology suite includes Lunit SCOPE products that analyze biomarkers for various cancers including those treated with immunotherapy, with specific solutions for PD-L1, HER2, and other important cancer markers.
Lunit's AI solutions are available at healthcare institutions across 50+ countries. Their technology is implemented in over 3,800 sites worldwide, including hospitals and research centers. You can contact Lunit directly through their website to inquire about availability at medical facilities near you or to explore partnership opportunities for healthcare providers.
Lunit SCOPE IO is an AI-powered biomarker analysis tool that helps predict patient response to immunotherapy. By analyzing tumor tissue samples, it provides insights into the tumor microenvironment and immune response. This helps oncologists make more informed treatment decisions, potentially increasing immunotherapy efficacy and improving patient outcomes for various cancer types.
While the description doesn't specify FDA approval status, Lunit's medical AI solutions are used globally across 50+ countries and 3,800+ sites, suggesting they meet regulatory requirements in multiple markets. Their technology is backed by extensive clinical research with 200+ studies. For specific approval status in your region, it's best to contact Lunit directly through their website.
Lunit's AI solutions are implemented in healthcare institutions worldwide, including notable partners like Inje University Paik Hospital. They collaborate with global research partners and have been featured in studies with organizations like the National Cancer Institute. While they don't publish a full client list, their technology is used across 3,800+ sites in 50+ countries.
Researchers interested in collaborating with Lunit can reach out through their partnership contact ([email protected]). Lunit actively engages in research collaborations, as evidenced by their work with institutions like the National Cancer Institute and AstraZeneca. They've participated in 200+ studies and welcome opportunities to advance cancer AI research through academic and clinical partnerships.
Lunit stands out through its comprehensive approach covering both cancer detection (radiology AI) and treatment optimization (oncology AI). Their technology is clinically validated with 200+ studies and implemented in 50+ countries. Lunit's consecutive recognition in the 'Digital Health 150' and partnerships with leading institutions demonstrate their leadership in medical AI innovation.
Yes, Lunit's AI solutions include capabilities for genetic mutation prediction. For example, their research includes studies on EGFR mutation prediction in non-small cell lung cancer (NSCLC), presented in collaboration with AstraZeneca. The Lunit SCOPE suite analyzes various biomarkers that can indicate genetic characteristics of tumors to guide precision treatment approaches.
Company Name:
Lunit
Website:
28.9K
Monthly Visits
3.3
Pages Per Visit
37.48%
Bounce Rate
154
Avg Time On Site
KR
62.16%
US
19.88%
IN
4.01%
VN
3.61%
TW
2.10%
Social
2.57%
Paid Referrals
0.49%
0.05%
Referrals
8.65%
Search
52.29%
Direct
35.89%
Keyword | Search Volume | Cost Per Click | Estimated Value |
---|---|---|---|
루닛 | 8.2K | $0.44 | $3.1K |
lunit | 4.3K | $-- | $930 |
루닛 채용 | 920 | $-- | $688 |
루닛 서범석 | -- | $-- | $470 |
fnslt | 200 | $-- | $275 |
0
0
12.4K
92.65%
390
100.00%
- Zebra Medical Vision
- Aidoc
- Arterys
- Quantib
- PathAI
Platform to discover, search and compare the best AI tools
© 2025 AISeekify.ai. All rights reserved.